Albireo to Present at 19th Annual BIO CEO & Invest

BOSTON, Feb. 06, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO ), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, is scheduled to present at the 19th Annual BIO CEO & Investor Conference at the Waldorf Astoria New York in New York City on Monday, February 13, 2017, at 9:30 a.m. ET.

A live audio webcast of the presentation will be accessible from the Investors page of Albireo’s website, www.albireopharma.com . To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay on the Events and Presentations section of the Investors page of Albireo’s website for at least two weeks following the event.

For additional information on the conference, visit https://www.bio.org/events/bio-ceo-investor-conference .  

About Albireo  Albireo is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s clinical pipeline includes two Phase 2 product candidates and one Phase 3 product candidate. Albireo was spun out from AstraZeneca in 2008.

Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com . 

Source: Albireo Pharma, Inc.

Investor Contact: Hans Vitzthum LifeSci Advisors, LLC. 212-915-2568 Media Contact: Heather Anderson 6 Degrees 980-938-0260 handerson@6degreespr.com